Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting

Salomon R, Rotem H, Katzenelenbogen Y, Weiner A, Saban NC, Feferman T, Amit I, Dahan R: Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nat Cancer 3(3), 287-302, doi: 10.1038/s43018-022-00329-6 (2022).

Categorised in:

This post was written by redakteur